Cara Therapeutics, Inc. (NASDAQ:CARA) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03), Briefing.com reports. During the same quarter in the prior year, the company earned ($0.42) EPS.

Shares of Cara Therapeutics (NASDAQ CARA) traded down $0.67 during mid-day trading on Friday, hitting $11.51. 438,755 shares of the company traded hands, compared to its average volume of 835,692.

A number of research analysts have recently commented on the stock. Piper Jaffray Companies set a $27.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 5th. Canaccord Genuity set a $25.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 5th. BidaskClub downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Cara Therapeutics in a research report on Wednesday, October 4th. Finally, Zacks Investment Research downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $25.46.

In other Cara Therapeutics news, CEO Derek T. Chalmers sold 16,000 shares of Cara Therapeutics stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Cara Therapeutics, Inc. (CARA) Releases Earnings Results, Misses Estimates By $0.03 EPS” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/cara-therapeutics-inc-cara-releases-earnings-results-misses-estimates-by-0-03-eps/1676582.html.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Earnings History for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.